Quest Diagnostics (NYSE:DGX – Get Free Report) announced its earnings results on Tuesday. The medical research company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.31 by $0.04, Briefing.com reports. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.49%. Quest Diagnostics’s revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm earned $2.30 earnings per share. Quest Diagnostics updated its FY 2024 guidance to 8.800-9.000 EPS and its FY24 guidance to $8.80-9.00 EPS.
Quest Diagnostics Trading Up 2.1 %
Shares of NYSE:DGX opened at $143.91 on Thursday. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. Quest Diagnostics has a 12-month low of $119.59 and a 12-month high of $150.59. The business has a 50 day moving average of $141.06 and a two-hundred day moving average of $134.39. The company has a market capitalization of $15.99 billion, a PE ratio of 19.37, a PEG ratio of 3.00 and a beta of 0.89.
Quest Diagnostics Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, July 22nd. Investors of record on Monday, July 8th were issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 2.08%. The ex-dividend date was Monday, July 8th. Quest Diagnostics’s dividend payout ratio (DPR) is 40.38%.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on DGX
Insider Transactions at Quest Diagnostics
In related news, SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the transaction, the senior vice president now directly owns 13,435 shares in the company, valued at approximately $1,880,900. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.79% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
See Also
- Five stocks we like better than Quest Diagnostics
- What is the Shanghai Stock Exchange Composite Index?
- How Much Should You Be Investing? Try Our Calculators
- What is Short Interest? How to Use It
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- The 3 Best Fintech Stocks to Buy Now
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.